Group CBT for Depression and AOD Disorders

Depression Clinical Trial

— BRIGHT2  

Official title:

Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01154309
• Other study ID #: R01DA020159
• Status: Completed
• Phase: Phase 1
• First received: June 29, 2010
• Last updated: November 10, 2011
• Start date: September 2006
• Est. completion date: September 2009

Study information

• Verified date: November 2011
• Source: RAND
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The investigators will adapt and test an existing treatment (group CBT for depression) for use in outpatient substance use treatment settings as delivered by trained substance use counselors. The investigators expect that treatment will lead to improved depression and substance use outcomes.

Description:

Aim 1. To adapt an existing group therapy (CBT for depression), creating a manualized treatment and accompanying implementation measures and tools for use with clients with persistent depressive symptoms and AOD disorders and to obtain preliminary assessments of the treatment from patient and provider perspectives.

Aim 2. To conduct a pilot test of the revised treatment in which we (a) demonstrate that when the therapy is implemented with fidelity, clinically significant reductions in depressive symptoms and AOD use occur; (b) estimate the likely effect size; and (c) investigate the underlying mechanisms of change, including both cognitive-behavioral and group processes and their relationship to depression and AOD treatment outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Enrolled in outpatient substance abuse program

• BDI II score >13

• Probable alcohol or substance use problem

Exclusion Criteria:

• Cognitive impairment (Short Blessed > 10)

• Probably bipolar or schizophrenic disorder

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Substance Use

Intervention

Behavioral:
• Group CBT for Depression and AOD Disorders
18 sessions of 2-hour group CBT

Locations

Country	Name	City	State
United States	Behavioral Health Services, Inc	Gardena	California

Sponsors (2)

Lead Sponsor	Collaborator
RAND	Behavioral Health Services, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reductions in depressive symptoms as measured by the BDI II		Post treatment	No
Primary	Reductions in AOD use		Post treatment	No